Placebo to teriflunomide 14 mg capsule
Sponsors
Novartis Pharma AG
Conditions
Multiple Sclerosis
Phase 3
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
Active, not recruitingCTIS2023-509345-12-00
Start: 2022-06-22Target: 464Updated: 2026-01-08
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
Active, not recruitingCTIS2023-509372-41-00
Start: 2022-01-30Target: 563Updated: 2026-01-26